Valeant Said to Cut Libido Pill Sales Force in Reshuffle
- Cuts said to affect gastrointestinal, dermatology divisions
- Drugmaker plans to relaunch Addyi sales later this year
Moody’s Senior VP: Major Asset Sale Negative for Valeant
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. has terminated the sales force for the female libido pill that it acquired last year for $1 billion, people familiar with the situation said, after the drug, Addyi, failed to gain traction in its first six months on the market.
Valeant plans to relaunch its sales effort for Addyi with an internal team it will build in the coming months, according to the people, who asked not to be identified because the matter was private. The drug will still be available in the meantime.